: Heart failure with reduced ejection fraction (HFrEF) is a pathological condition still characterized by high rates of mortality and disease exacerbation frequently leading to hospitalization, thus there is a continuous need for pharmacological treatments impacting on disease stability and long-term prognosis. Moreover, the phenotype of heart failure patients is continuously changing over time, and the development of new heart failure drugs is crucial to promote a personalized and targeted approach. In recent years, several therapeutic innovations have emerged in the landscape of acute and chronic HFrEF, largely changing and improving our approach to the disease. Various studies on new drugs and experimental therapeutic approaches are ongoing. The present review discusses the latest data on both recently approved drugs and developing therapeutic targets, in order to provide a critical overview for an informed and optimal approach to such a complex disease.

Innovations in medical therapy of heart failure with reduced ejection fraction / Mercurio, Valentina; Ambrosio, Giuseppe; Correale, Michele; Dini, Frank L; Ghio, Stefano; Nodari, Savina; Palazzuoli, Alberto; Ruocco, Gaetano; Pedrinelli, Roberto; Mercuro, Giuseppe; Filardi, Pasquale Perrone; Indolfi, Ciro; Agostoni, Piergiuseppe; Tocchetti, Carlo G; Paolillo, Stefania. - In: JOURNAL OF CARDIOVASCULAR MEDICINE. - ISSN 1558-2027. - 24:Suppl 1(2023), pp. e47-e54. [10.2459/JCM.0000000000001413]

Innovations in medical therapy of heart failure with reduced ejection fraction

Mercurio, Valentina;Ruocco, Gaetano;Filardi, Pasquale Perrone;Indolfi, Ciro;Tocchetti, Carlo G;Paolillo, Stefania
2023

Abstract

: Heart failure with reduced ejection fraction (HFrEF) is a pathological condition still characterized by high rates of mortality and disease exacerbation frequently leading to hospitalization, thus there is a continuous need for pharmacological treatments impacting on disease stability and long-term prognosis. Moreover, the phenotype of heart failure patients is continuously changing over time, and the development of new heart failure drugs is crucial to promote a personalized and targeted approach. In recent years, several therapeutic innovations have emerged in the landscape of acute and chronic HFrEF, largely changing and improving our approach to the disease. Various studies on new drugs and experimental therapeutic approaches are ongoing. The present review discusses the latest data on both recently approved drugs and developing therapeutic targets, in order to provide a critical overview for an informed and optimal approach to such a complex disease.
2023
Innovations in medical therapy of heart failure with reduced ejection fraction / Mercurio, Valentina; Ambrosio, Giuseppe; Correale, Michele; Dini, Frank L; Ghio, Stefano; Nodari, Savina; Palazzuoli, Alberto; Ruocco, Gaetano; Pedrinelli, Roberto; Mercuro, Giuseppe; Filardi, Pasquale Perrone; Indolfi, Ciro; Agostoni, Piergiuseppe; Tocchetti, Carlo G; Paolillo, Stefania. - In: JOURNAL OF CARDIOVASCULAR MEDICINE. - ISSN 1558-2027. - 24:Suppl 1(2023), pp. e47-e54. [10.2459/JCM.0000000000001413]
File in questo prodotto:
File Dimensione Formato  
mercurio paolillo jcm Innovations_in_medical_therapy_of_heart_failure.82.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 834.8 kB
Formato Adobe PDF
834.8 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/917866
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact